Clinical Trial Search

Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage

Primary: Change in Baseline A1C and A1C Measured at 3 Month Intervals up to 12 Months — 9.00; 6.81; 7.13; 7.26 percentage of glycosylated hemoglobin

Primary: ß-cell Response Measured by Hyperglycemic Clamp — 3.65; 3.58; 3.60; 3.73 nmol/L — p=>0.05

Primary: Change in Average Daily Total Insulin Use — -6.72; -5.25; -1.37; -7.59 Units/day

Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year

Primary: Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements — -2.09; 2.83; -1.92; -1.10 mg/dL

Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24

Primary: Fasting Insulin — 12.7; 13.1; 16.4; 13.9 μU/mL

Primary: Hospital Length of Stay — 2.7; 3.1 days — p=0.58

Primary: Change in Weekly Mean Blood Glucose From Week 4 to Week 16 — 4.6; 8.1; 29.5 mg/dL

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. — -0.4; -1.4; 0.1; 0.3 ng per ml

Primary: Mean AM BG (mg/dl) — 144; 155 mg/dl

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL

Primary: ß-cell Response Measured by Hyperglycemic Clamp — 4.82; 4.18; 6.92; 5.95 nmol/L — p=>0.05

Primary: Change in HbA1c — -0.25; -0.4 Percent — p=0.2539

Primary: Change in A1c at the End of Study Period — -2.38; -0.83 % change of A1c

Primary: Normoglycemia on Therapy — 14; 1; 19; 1 Participants

Primary: Insulin Sensitivity — 0.1; 0.07 mL/kg/min per uU/mL

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min

Primary: Number of All Consented Participants — 12; 12 Participants

Primary: Blood Glucose Measurements — 97.38; 95.04; 97.00; 92.38 mg/dL

Primary: Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care — -0.16; -0.12 liters

Primary: Change in A1c — 9.74; 7.98 percent HbA1c — p=0.004

Primary: Hemoglobin A1c (HbA1c) at 36 Week Endpoint — 7.66; 7.49 percent HbA1c — p=0.097

Primary: Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) — -4.94; -10.00; -1.21; -11.42 mg/dL…

Primary: The Number of Participants Who Achieved a Hemoglobin A1C <7% — 5; 12 Participants

Primary: Change From Baseline in A1C at Week 24 — -0.59; -0.03 Percent — p=<0.001

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.27; -0.85 Percentage of HbA1c — p=<0.001